A Phase 3 interventional study of S-217622 and Placebo in SARS-CoV-2 Infection, sponsored by Shionogi. Completed at 196 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Shionogi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 110th largest by enrollment of the 1,321 interventional ones that give a count, is one of 223 that started in 2022, is one of 174 in phase 3, and was the 1,430th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 223 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,093 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.
Shionogi has 7 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Note: Current use of some is exclusionary, due to concern for possible drug-drug interaction (DDI) with S-217622.
Exclusion Criteria:
Note: Paxlovid use for a prior episode of COVID-19 is permitted.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
S-217622 will be administered orally for 5 days.
Drug: S-217622
Placebo matching to S-217622 will be administered orally for 5 days.
Drug: Placebo
Administered as a round tablet.
Administered as a round tablet.
Time to Sustained Symptom Resolution
Time to sustained symptom resolution was defined as the time from start of study intervention to the first day of 2 consecutive days with complete resolution of COVID-19 symptoms on participant self-assessment and alive and without hospitalization for any reason by Day 29. Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19.
Time frame: Up to Day 29
Change From Baseline at Day 4 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA Levels on Nasopharyngeal (NP) Swabs
NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by quantitative log10 polymerase chain reaction (PCR). Results reported as log10 (RNA copies/milliliter \[mL\]).
Time frame: Baseline, Day 4
Number of Participants Who Experienced Hospitalization (Adjudicated) or Death Due to Any Cause
Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19. Hospitalization was adjudicated to be COVID-19-related. All deaths regardless of occurrence outside of hospital or during hospitalization (not adjudicated) are reported.
Time frame: Up to Day 29
Time to Sustained Symptom Resolution in the mITT1 Set
Time to sustained symptom resolution was defined as the time from start of study intervention to the first day of 2 consecutive days with complete resolution of COVID-19 symptoms on participant self-assessment and alive and without hospitalization for any reason by Day 29. Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19. Wald confidence interval reported.
Time frame: Up to Day 29
Median Change From Baseline at Day 8 in SARS-CoV-2 RNA Levels on NP Swabs
NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by quantitative log10 PCR.
Time frame: Baseline, Day 8
Number of Participants With Persistent and/or Late-Onset Symptoms of COVID-19 at Week 12
The number of participants with persistent and/or late-onset symptoms of COVID-19 at Week 12 based on participant assessment of the 5 symptoms specified by the World Health Organization (WHO) (fatigue, shortness of breath/difficulty breathing, difficulty with concentration/ thinking, difficulty reasoning/solving problems, and memory loss) plus taste disturbance and smell disturbance.
Time frame: Week 12
Time to Sustained Resolution of 6 Targeted Symptoms and Being Alive and Without Hospitalization for Any Reason by Day 29
The time to sustained symptom resolution was defined as the first day of 2 consecutive days with complete resolution of COVID-19 symptoms on participant self-assessment and being alive and without hospitalization for any reason by Day 29. Data are reported for time (days) from start of ensitrelvir or placebo (Day 1) until sustained resolution based on assessments for 2 consecutive days of 6 targeted symptoms (nasal obstruction or congestion, nasal discharge, sore throat, cough, feeling feverish, and fatigue) and being alive and not hospitalized for any reason. Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19.
Time frame: Day 1 through Day 29
Time to Sustained Resolution of Targeted Symptoms (Excluding Loss of Taste and Loss of Smell) and Being Alive and Without Hospitalization for Any Reason by Day 29
The time to sustained symptom resolution was defined as the first day of 2 consecutive days with complete resolution of COVID-19 symptoms on participant self-assessment and being alive and without hospitalization for any reason by Day 29. Time (days) from start of ensitrelvir or placebo (Day 1) until sustained resolution (where cough and fatigue were considered resolved if they remain mild) based on assessments for 2 consecutive days of all targeted symptoms excluding loss of taste and loss of smell (cough, shortness of breath or difficulty breathing, feeling feverish, chills, fatigue, body pain or muscle pain or aches, diarrhea, nausea, vomiting, headache, sore throat, nasal obstruction or congestion, and nasal discharge) and being alive and not hospitalized for any reason by Day 29. Hospitalization was ≥24 hours of acute care, in a hospital or similar acute care facility (emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19).
Time frame: Day 1 through Day 29
Number of Participants With Undetectable SARS-CoV-2 on NP Swabs on Day 4 and Day 8
NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by viral titer by culture.
Time frame: Day 4 and Day 8
Number of Participants Experiencing Hospitalization (All Cause) or Death Due to Any Cause
Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs. All deaths regardless of occurrence outside of hospital or during hospitalization (not adjudicated) are reported.
Time frame: Up to Day 29
Number of Participants With NP SARS-CoV-2 RNA Levels Below the Lower Limit of Quantification on Day 4 and Day 8
NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by log10 quantitative PCR.
Time frame: Day 4 and Day 8
Median Change From Baseline at Day 4 and Day 8 in SARS-CoV-2 RNA by Quantitative PCR in NP Swabs
NP swabs were collected by staff during in-person visits per protocol for measurement of log10 SARS-CoV-2 RNA levels by quantitative PCR.
Time frame: Baseline, Day 4, Day 8
Time to Self-Reported Return to Usual (Pre-COVID-19) Health
Participants kept a log of symptoms and major events in their study diary. The time to self-reported return to health (in days) was derived as: (the date of self-reported return to usual \[pre-COVID-19 health\] - (the date of first dose of study intervention) + 1.
Time frame: Day 1 up to Day 29
Number of Participants Reaching a Score ≥2, ≥3, ≥4, ≥5, ≥6, ≥7, or ≥8 on the WHO Ordinal Scale
The severity of COVID-19 disease was assessed using the WHO ordinal scale. The scale ranged from 1 to 8 and focuses primarily on the participant's oxygen need when they first came to the hospital. Scores include: 1 = no limitation of activities; 2 = limitation of activities; 3 = hospitalized no oxygen therapy; 4 = oxygen by mask or nasal prongs; 5 = non-invasive ventilation or high flow oxygen; 6 = intubation and mechanical ventilation; 7 = ventilation and additional organ support, pressors, renal replacement therapy, extra corporeal membrane oxygenation; 8 = death. Higher scores indicated greater severity of illness and a need for more intensive medical support.
Time frame: Day 29
Change From Baseline at Day 29 in Resting Peripheral Oxygen Saturation
Resting peripheral oxygen saturation was measured as the percentage of oxygen transported throughout the participant's body. An increase in percentage indicated an increased oxygen supply throughout the body.
Time frame: Baseline, Day 29
Number of Participants With Resting Peripheral Oxygen Saturation <96% Versus ≥96%
Resting peripheral oxygen saturation was measured as the percentage of oxygen transported throughout the participant's body. Saturation levels at ≥96% indicated effective oxygen transportation throughout the body. A decrease in percentage indicated decreased oxygen supply throughout the body.
Time frame: Up to Day 29
Severity of Persistent and/or Late-Onset Symptoms of COVID-19 at Week 24
A participant was considered to have persistent and/or late-onset symptoms if either 1 of the following criteria was met: occurrence of at least 1 of the following symptoms at Week 24: difficulty with concentration/thinking, difficulty reasoning/solving problems, or memory loss; or occurrence of at least 1 of the following symptoms at Week 24: fatigue, shortness of breath/difficulty breathing, taste disturbance, or smell disturbance. Symptom severity assessed as: None; Mild; Moderate; Severe; At least Mild.
Time frame: Week 24
Number of Participants With Symptomatic Viral Rebound Between Day 6 and Day 29
NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by log10 quantitative PCR. Symptomatic viral rebound was defined as an increase in NP SARS-CoV-2 RNA levels by quantitative PCR or an increase in NP SARS-CoV-2 viral culture.
Time frame: Day 6 up to Day 29
Number of Participants With Viral Rebound Between Day 6 and Day 29
NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by quantitative PCR. Viral rebound was defined as an increase in quantitative NP SARS-CoV-2 viral culture or NP SARS CoV-2 RNA levels by quantitative PCR.
Time frame: Day 6 up to Day 29
Change From Baseline at Week 24 in Short Form 36 Version 2.0 (SF-36 V2) Quality of Life Score
The SF-36v2 is a 36-item, participant-reported survey of participant health that measures 8 scales: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. Each component was directly transformed into a 0 to 100 scale on the assumption that each question carried equal weight. A score of 0 was equal to maximum disability, and a score of 100 indicated no disability. Mean change could range from -100 to 100. A positive mean change indicated an improved outcome.
Time frame: Baseline, Week 24
Change From Baseline at Week 24 in EuroQol-5 Dimension 5 Level (EQ-5D-5L): Visual Analog Scale (VAS)
The EQ-5D-5L VAS is an instrument for self-reported assessment that ranks participant health status. Participants self-rate their health status using a scale of best health imaginable (100) to worst health imaginable (0). An increase in score indicates an improved health status.
Time frame: Baseline, Week 24
Number of Participants With a Response as Measured by the Post-Acute COVID-19 Questionnaire
Participants completed a post-acute COVID-19 questionnaire at each scheduled visit. The questionnaire is a survey instrument used to help measure functional health and health-related quality of life post-acute COVID-19. One of the items the questionnaire captures was whether the participant sought urgent medical care at an emergency room or clinic for specified symptoms (answered 'Yes' or 'No'). Symptoms ranged from cough and shortness of breath or difficult breathing to difficulty reasoning and solving problems and memory loss (short or long term). The number of participants answering 'Yes' to this question is reported.
Time frame: Week 24
Number of Participants Who Experienced Death Due to Any Cause
All participants in the mITT set who experienced death due to any cause are reported. All deaths regardless of occurrence outside of hospital or during hospitalization (not adjudicated) are reported.
Time frame: Baseline through Week 24
Plasma Concentration of Ensitrelvir at Day 4
Plasma samples were collected at specified timepoints to measure ensitrelvir levels. Results reported as micrograms/milliliter (ug/mL).
Time frame: Day 4 (up to 90 minutes postdose)
| Milestone | Ensitrelvir | Placebo |
|---|---|---|
| Started | 1042 | 1051 |
| Received at least 1 dose of study drug | 1038 | 1047 |
| Modified intent-to-treat (mitt) set | 945 | 943 |
| Viral culture set | 309 | 292 |
| Safety analysis set | 1037 | 1048 |
| Pharmacokinetic (pk) set | 222 | 65 |
| Completed | 980 | 994 |
| Not completed | 62 | 57 |
| Withdrew: Sponsor decision | 4 | 2 |
| Withdrew: Physician decision | 2 | 3 |
| Withdrew: Lost to follow-up | 25 | 25 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Other than specified | 7 | 6 |
| Withdrew: Withdrawal by subject | 23 | 18 |
Time to sustained symptom resolution was defined as the time from start of study intervention to the first day of 2 consecutive days with complete resolution of COVID-19 symptoms on participant self-assessment and alive and without hospitalization for any reason by Day 29. Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19.
| days | Ensitrelvir | Placebo |
|---|---|---|
| Time to Sustained Symptom Resolution | 12.5 (11.97 to 13.08) | 13.1 (12.56 to 13.68) |
NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by quantitative log10 polymerase chain reaction (PCR). Results reported as log10 (RNA copies/milliliter \[mL\]).
| log10 (RNA copies/mL) | Ensitrelvir | Placebo |
|---|---|---|
| Change From Baseline at Day 4 in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA Levels on Nasopharyngeal (NP) Swabs | -2.7435 ± 2.09428 | -1.9630 ± 2.07001 |
Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19. Hospitalization was adjudicated to be COVID-19-related. All deaths regardless of occurrence outside of hospital or during hospitalization (not adjudicated) are reported.
| Participants | Ensitrelvir | Placebo |
|---|---|---|
| mITT | 3 | 1 |
| mITT1 | 3 | 1 |
Time to sustained symptom resolution was defined as the time from start of study intervention to the first day of 2 consecutive days with complete resolution of COVID-19 symptoms on participant self-assessment and alive and without hospitalization for any reason by Day 29. Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19. Wald confidence interval reported.
| days | Ensitrelvir | Placebo |
|---|---|---|
| Time to Sustained Symptom Resolution in the mITT1 Set | 12.6 (12.03 to 13.09) | 13.1 (12.62 to 13.68) |
NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by quantitative log10 PCR.
| log10 (RNA copies/mL) | Ensitrelvir | Placebo |
|---|---|---|
| Median Change From Baseline at Day 8 in SARS-CoV-2 RNA Levels on NP Swabs | -4.6000 (-5.6905 to -2.4450) | -4.1710 (-5.3300 to -2.2550) |
The number of participants with persistent and/or late-onset symptoms of COVID-19 at Week 12 based on participant assessment of the 5 symptoms specified by the World Health Organization (WHO) (fatigue, shortness of breath/difficulty breathing, difficulty with concentration/ thinking, difficulty reasoning/solving problems, and memory loss) plus taste disturbance and smell disturbance.
| Participants | Ensitrelvir | Placebo |
|---|---|---|
| Week 12: mITT | 227 | 221 |
| Week 12: mITT1 | 256 | 253 |
The time to sustained symptom resolution was defined as the first day of 2 consecutive days with complete resolution of COVID-19 symptoms on participant self-assessment and being alive and without hospitalization for any reason by Day 29. Data are reported for time (days) from start of ensitrelvir or placebo (Day 1) until sustained resolution based on assessments for 2 consecutive days of 6 targeted symptoms (nasal obstruction or congestion, nasal discharge, sore throat, cough, feeling feverish, and fatigue) and being alive and not hospitalized for any reason. Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19.
| days | Ensitrelvir | Placebo |
|---|---|---|
| Time to Sustained Resolution of 6 Targeted Symptoms and Being Alive and Without Hospitalization for Any Reason by Day 29 | 11.3 (10.75 to 11.82) | 12.0 (11.45 to 12.56) |
The time to sustained symptom resolution was defined as the first day of 2 consecutive days with complete resolution of COVID-19 symptoms on participant self-assessment and being alive and without hospitalization for any reason by Day 29. Time (days) from start of ensitrelvir or placebo (Day 1) until sustained resolution (where cough and fatigue were considered resolved if they remain mild) based on assessments for 2 consecutive days of all targeted symptoms excluding loss of taste and loss of smell (cough, shortness of breath or difficulty breathing, feeling feverish, chills, fatigue, body pain or muscle pain or aches, diarrhea, nausea, vomiting, headache, sore throat, nasal obstruction or congestion, and nasal discharge) and being alive and not hospitalized for any reason by Day 29. Hospitalization was ≥24 hours of acute care, in a hospital or similar acute care facility (emergency rooms, urgent care clinics, or facilities instituted to address medical needs of those with COVID-19).
| days | Ensitrelvir | Placebo |
|---|---|---|
| Time to Sustained Resolution of Targeted Symptoms (Excluding Loss of Taste and Loss of Smell) and Being Alive and Without Hospitalization for Any Reason by Day 29 | 12.2 (11.61 to 12.72) | 12.8 (12.20 to 13.32) |
NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by viral titer by culture.
| Participants | Ensitrelvir | Placebo |
|---|---|---|
| Day 4 | 274 | 210 |
| Day 8 | 283 | 267 |
Hospitalization was defined as ≥24 hours of acute care in a hospital or similar acute care facility, including emergency rooms, urgent care clinics, or facilities instituted to address medical needs. All deaths regardless of occurrence outside of hospital or during hospitalization (not adjudicated) are reported.
| Participants | Ensitrelvir | Placebo |
|---|---|---|
| Number of Participants Experiencing Hospitalization (All Cause) or Death Due to Any Cause | 3 | 2 |
NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by log10 quantitative PCR.
| Participants | Ensitrelvir | Placebo |
|---|---|---|
| Day 4 | 415 | 345 |
| Day 8 | 707 | 666 |
NP swabs were collected by staff during in-person visits per protocol for measurement of log10 SARS-CoV-2 RNA levels by quantitative PCR.
| log10 (RNA copies/mL) | Ensitrelvir | Placebo |
|---|---|---|
| Day 4 | -1.250 (-4.50 to 3.00) | -1.000 (-5.00 to 3.00) |
| Day 8 | -1.250 (-5.00 to -.025) | -1.000 (-5.00 to 0.50) |
Participants kept a log of symptoms and major events in their study diary. The time to self-reported return to health (in days) was derived as: (the date of self-reported return to usual \[pre-COVID-19 health\] - (the date of first dose of study intervention) + 1.
| days | Ensitrelvir | Placebo |
|---|---|---|
| Time to Self-Reported Return to Usual (Pre-COVID-19) Health | 11.4 (10.83 to 11.93) | 11.9 (11.37 to 12.50) |
The severity of COVID-19 disease was assessed using the WHO ordinal scale. The scale ranged from 1 to 8 and focuses primarily on the participant's oxygen need when they first came to the hospital. Scores include: 1 = no limitation of activities; 2 = limitation of activities; 3 = hospitalized no oxygen therapy; 4 = oxygen by mask or nasal prongs; 5 = non-invasive ventilation or high flow oxygen; 6 = intubation and mechanical ventilation; 7 = ventilation and additional organ support, pressors, renal replacement therapy, extra corporeal membrane oxygenation; 8 = death. Higher scores indicated greater severity of illness and a need for more intensive medical support.
| Participants | Ensitrelvir | Placebo |
|---|---|---|
| Score of ≥2 | 15 | 17 |
| Score of ≥3 | 1 | 0 |
| Score of ≥4 | 0 | 0 |
| Score of ≥5 | 0 | 0 |
| Score of ≥6 | 0 | 0 |
| Score of ≥7 | 0 | 0 |
| Score of ≥8 | 0 | 0 |
Resting peripheral oxygen saturation was measured as the percentage of oxygen transported throughout the participant's body. An increase in percentage indicated an increased oxygen supply throughout the body.
| percentage of oxygen | Ensitrelvir | Placebo |
|---|---|---|
| Change From Baseline at Day 29 in Resting Peripheral Oxygen Saturation | 0.7 ± 1.57 | 0.8 ± 1.48 |
Resting peripheral oxygen saturation was measured as the percentage of oxygen transported throughout the participant's body. Saturation levels at ≥96% indicated effective oxygen transportation throughout the body. A decrease in percentage indicated decreased oxygen supply throughout the body.
| Participants | Ensitrelvir | Placebo |
|---|---|---|
| Oxygen Saturation <96% | 28 | 24 |
| Oxygen Saturation ≥96% | 846 | 843 |
A participant was considered to have persistent and/or late-onset symptoms if either 1 of the following criteria was met: occurrence of at least 1 of the following symptoms at Week 24: difficulty with concentration/thinking, difficulty reasoning/solving problems, or memory loss; or occurrence of at least 1 of the following symptoms at Week 24: fatigue, shortness of breath/difficulty breathing, taste disturbance, or smell disturbance. Symptom severity assessed as: None; Mild; Moderate; Severe; At least Mild.
| Participants | Ensitrelvir | Placebo |
|---|---|---|
| None (mITT) | 545 | 537 |
| Mild (mITT) | 15 | 26 |
| Moderate (mITT) | 7 | 3 |
| Severe (mITT) | 1 | 3 |
| At Least Mild (mITT) | 23 | 32 |
| None (mITT1) | 619 | 611 |
| Mild (mITT1) | 18 | 30 |
| Moderate (mITT1) | 7 | 3 |
| Severe (mITT1) | 1 | 465 |
| At Least Mild (mITT1) | 26 | 37 |
NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by log10 quantitative PCR. Symptomatic viral rebound was defined as an increase in NP SARS-CoV-2 RNA levels by quantitative PCR or an increase in NP SARS-CoV-2 viral culture.
| Participants | Ensitrelvir | Placebo |
|---|---|---|
| Viral Culture: mITT | 0 | 0 |
| Quantitative PCR: mITT | 0 | 0 |
| Viral Culture: mITT1 | 0 | 0 |
| Quantitative PCR: mITT1 | 0 | 0 |
NP swabs were collected by staff during in-person visits for measurement of SARS-CoV-2 RNA levels by quantitative PCR. Viral rebound was defined as an increase in quantitative NP SARS-CoV-2 viral culture or NP SARS CoV-2 RNA levels by quantitative PCR.
| Participants | Ensitrelvir | Placebo |
|---|---|---|
| Viral Culture: mITT | 6 | 13 |
| Quantitative PCR: mITT | 23 | 21 |
| Viral Culture: mITT1 | 7 | 13 |
| Quantitative PCR: mITT1 | 24 | 23 |
The SF-36v2 is a 36-item, participant-reported survey of participant health that measures 8 scales: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. Each component was directly transformed into a 0 to 100 scale on the assumption that each question carried equal weight. A score of 0 was equal to maximum disability, and a score of 100 indicated no disability. Mean change could range from -100 to 100. A positive mean change indicated an improved outcome.
| units on a scale | Ensitrelvir | Placebo |
|---|---|---|
| Physical Functioning | 22.447 ± 26.7264 | 22.331 ± 26.7551 |
| Role Physical | 12.831 ± 25.2642 | 14.926 ± 25.8196 |
| Bodily Pain | 20.112 ± 25.7459 | 20.316 ± 25.1820 |
| General Health | 16.367 ± 19.6536 | 15.985 ± 19.5233 |
| Vitality | 10.324 ± 20.8770 | 10.905 ± 20.8562 |
| Social Functioning | 10.485 ± 24.0657 | 9.193 ± 23.2424 |
| Role Emotional | 6.853 ± 23.1999 | 7.682 ± 23.9112 |
| Mental Health | 7.159 ± 20.0092 | 7.401 ± 19.2495 |
The EQ-5D-5L VAS is an instrument for self-reported assessment that ranks participant health status. Participants self-rate their health status using a scale of best health imaginable (100) to worst health imaginable (0). An increase in score indicates an improved health status.
| units on a Scale | Ensitrelvir | Placebo |
|---|---|---|
| Change From Baseline at Week 24 in EuroQol-5 Dimension 5 Level (EQ-5D-5L): Visual Analog Scale (VAS) | 26.4 ± 17.35 | 24.6 ± 17.30 |
Participants completed a post-acute COVID-19 questionnaire at each scheduled visit. The questionnaire is a survey instrument used to help measure functional health and health-related quality of life post-acute COVID-19. One of the items the questionnaire captures was whether the participant sought urgent medical care at an emergency room or clinic for specified symptoms (answered 'Yes' or 'No'). Symptoms ranged from cough and shortness of breath or difficult breathing to difficulty reasoning and solving problems and memory loss (short or long term). The number of participants answering 'Yes' to this question is reported.
| Participants | Ensitrelvir | Placebo |
|---|---|---|
| Number of Participants With a Response as Measured by the Post-Acute COVID-19 Questionnaire | 25 | 21 |
All participants in the mITT set who experienced death due to any cause are reported. All deaths regardless of occurrence outside of hospital or during hospitalization (not adjudicated) are reported.
| Participants | Ensitrelvir | Placebo |
|---|---|---|
| Number of Participants Who Experienced Death Due to Any Cause | 0 | 2 |
Plasma samples were collected at specified timepoints to measure ensitrelvir levels. Results reported as micrograms/milliliter (ug/mL).
| ug/mL | Ensitrelvir |
|---|---|
| Plasma Concentration of Ensitrelvir at Day 4 | 68.492 ± 170.6613 |
Collected over Day 1 through Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ensitrelvir | 0/1,037 (0%) | 11/1,037 (1.1%) | 472/1,037 (45.5%) |
| Placebo | 2/1,048 (0.2%) | 13/1,048 (1.2%) | 474/1,048 (45.2%) |
| Event | Ensitrelvir | Placebo |
|---|---|---|
| Lower respiratory tract infectionInfections and infestations | 0/1037 | 2/1048 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/587 | 1/568 |
| EndometriosisReproductive system and breast disorders | 0/587 | 1/568 |
| AppendicitisInfections and infestations | 1/1037 | 1/1048 |
| PneumoniaInfections and infestations | 1/1037 | 0/1048 |
| Anal fistulaGastrointestinal disorders | 1/1037 | 0/1048 |
| Idiopathic pancreatitisGastrointestinal disorders | 1/1037 | 0/1048 |
| Hepatic enzyme increasedInvestigations | 1/1037 | 0/1048 |
| Lymphocyte count decreasedInvestigations | 1/1037 | 0/1048 |
| Cerebral atrophyNervous system disorders | 1/1037 | 0/1048 |
| Event | Ensitrelvir | Placebo |
|---|---|---|
| HypertriglyceridaemiaMetabolism and nutrition disorders | 167/1037 | 154/1048 |
| Creatinine renal clearance decreasedInvestigations | 111/1037 | 101/1048 |
| Blood triglycerides increasedInvestigations | 107/1037 | 98/1048 |
| HyperglycaemiaMetabolism and nutrition disorders | 93/1037 | 92/1048 |
| Low density lipoprotein increasedInvestigations | 78/1037 | 84/1048 |
| HeadacheNervous system disorders | 40/1037 | 59/1048 |
| Blood glucose increasedInvestigations | 46/1037 | 58/1048 |
| Alanine aminotransferase increasedInvestigations | 38/1037 | 58/1048 |
Modified Intent-to-treat (mITT) Set: all randomized participants who took at least 1 dose of ensitrelvir or placebo and who started intervention within 3 days of symptom onset.
| Age, Continuous(years) | Ensitrelvir | Placebo | Total |
|---|---|---|---|
| Mean | 40.4 ± 13.68 | 40.1 ± 13.80 | 40.3 ± 13.74 |
| Sex: Female, Male(Participants) | Ensitrelvir | Placebo | Total |
|---|---|---|---|
| Female | 540 | 506 | 1046 |
| Male | 405 | 437 | 842 |
| Ethnicity (NIH/OMB)(Participants) | Ensitrelvir | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 430 | 421 | 851 |
| Not Hispanic or Latino | 508 | 511 | 1019 |
| Unknown or Not Reported | 7 | 11 | 18 |
| Race (NIH/OMB)(Participants) | Ensitrelvir | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 9 | 5 | 14 |
| Asian | 387 | 396 | 783 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 77 | 92 | 169 |
| White | 403 | 383 | 786 |
| More than one race | 5 | 3 | 8 |
| Unknown or Not Reported | 64 | 64 | 128 |
| Coronavirus Disease 2019 (COVID-19) Vaccination Status(Participants) | Ensitrelvir | Placebo | Total |
|---|---|---|---|
| Not vaccinated | 245 | 208 | 453 |
| Completed primary series with last vaccine >3 months prior to enrollment | 675 | 714 | 1389 |
| Completed primary series with last vaccine ≤3 months prior to enrollment | 21 | 18 | 39 |
| Missing | 4 | 3 | 7 |
Showing the first 100 of 196 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2022 to primary completion in Jan 2024, 17 months.
Results were first posted in Aug 2026, 2 years 7 months after primary completion. A results delay was requested in Jan 2025.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 17 months is above that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ensitrelvir